

Supplementary Material: Establishment of a Pretreatment Nomogram to Predict the 6-Month Mortality Rate of Patients with Advanced Biliary Tract Cancers Undergoing Gemcitabine-based Chemotherapy

Chiao-En Wu, Wen-Kuan Huang, Wen-Chi Chou, Chia-Hsun Hsieh, John Wen-Cheng Chang, Cheng-Yu Lin, Chun-Nan Yeh and Jen-Shi Chen

Table S1. Characteristics of patients stratified by chemotherapy regimens.

Characteristic	G alone (<i>n</i> = 43)	G-based double C/T (<i>n</i> = 159)	<i>p</i> -value
Age (years), median (IQR)	66.0 (15.0)	62.0 (14.0)	0.023
≤65	20 (46.5)	99 (62.3)	0.063
>65	23 (53.5)	60 (37.7)	
Gender			0.351
Male	19 (44.2)	83 (52.2)	
Female	24 (55.8)	76 (47.8)	
ICD-10 cancer site			<0.001
C22.1-ICCA	14 (32.6)	106 (66.7)	
C23/C24.9-GB/others	10 (23.3)	27 (17.0)	
C24.0-ECCA	17 (39.5)	21 (13.2)	
C24.1-Ampullary	2 (4.7)	5 (3.1)	
Performance score			0.004
0/1	31 (72.1)	142 (89.3)	
2/3	12 (27.9)	17 (10.7)	
NLR, median (IQR)	4.06 (5.03)	3.88 (3.56)	0.510
<3.95	21 (48.8)	83 (52.2)	0.695
≥3.95	22 (51.2)	76 (47.8)	
MLR, median (IQR)	0.35 (0.40)	0.37 (0.31)	0.541
<0.39	24 (55.8)	82 (51.6)	0.621
≥0.39	19 (44.2)	77 (48.4)	
PLR, median (IQR)	184.37 (123.95)	152.60 (121.94)	0.106
<147.2	14 (32.6)	70 (44.0)	0.176
≥147.2	29 (67.4)	89 (56.0)	
Albumin (g/dL), median (IQR)	3.34 (0.90)	3.80 (0.92)	0.106
<3.5	23 (59.0)	45 (31.9)	0.002
≥3.5	16 (41.0)	96 (68.1)	
ALT (U/L), median (IQR)	37.0 (46.0)	30.0 (35.3)	0.348
≤36	21 (48.8)	97 (61.4)	0.138
>36	22 (51.2)	61 (38.6)	
Bilirubin (mg/dL), median (IQR)	1.15 (1.10)	0.70 (0.70)	0.002
≤1.3	23 (54.8)	121 (77.1)	0.004
>1.3	19 (45.2)	36 (22.9)	
ALP (U/L), median (IQR)	255.00 (255.00)	159.00 (153.00)	0.008
≤94	6 (14.0)	38 (23.9)	0.161
>94	37 (86.0)	121 (76.1)	
Creatinine (mg/dL), median (IQR)	0.62 (0.48)	0.65 (0.32)	0.591
≤1.27	40 (93.0)	154 (96.9)	0.371

>1.27	3 (7.0)	5 (3.1)	
CA199 (U/mL), median (IQR)	550.80 (960.10)	165.0 (1686.43)	0.038
<37	3 (8.1)	47 (30.1)	0.006
≥37	34 (91.9)	109 (69.9)	
CEA (ng/mL), median (IQR)	2.45 (13.64)	3.10 (8.58)	0.821
≤5	24 (61.5)	99 (62.7)	0.897
>5	15 (38.5)	59 (37.3)	
Biliary drainage			0.014
None	21 (48.8)	111 (69.8)	
Internal stenting	4 (9.3)	9 (5.7)	
PTCD	18 (41.9)	33 (20.8)	
Both	0	6 (3.8)	
Tumor involvement			
Primary tumor			>0.999
No	3 (7.0)	12 (7.5)	
Yes	40 (93.0)	147 (92.5)	
Regional lymphadenopathy			0.930
No	16 (37.2)	58 (36.5)	
Yes	27 (62.8)	101 (63.5)	
Lung			0.023
No	41 (95.3)	129 (81.1)	
Yes	2 (4.7)	30 (18.9)	
Bone			0.201
No	42 (97.7)	144 (90.6)	
Yes	1 (2.3)	15 (9.4)	
Liver			0.390
No	28 (65.1)	92 (57.9)	
Yes	15 (34.9)	67 (42.1)	
Peritoneum			0.304
No	38 (88.4)	130 (81.8)	
Yes	5 (11.6)	29 (18.2)	
Distant lymphadenopathy			0.377
No	39 (90.7)	136 (85.5)	
Yes	4 (9.3)	23 (14.5)	
Response			0.468
CR/RR	6 (14.0)	18 (11.3)	
SD	8 (18.6)	17 (10.7)	
PD	15 (34.9)	69 (43.4)	
NA	14 (32.6)	55 (34.6)	

IQR, interquartile range, CR, complete response; PR, partial response; SD, stable disease, PD, progressive disease, NA, not assessed; ALP, alkaline phosphatase; ALT, alanine aminotransferase; NLR, neutrophil to lymphocyte ratio; MLR, monocyte to lymphocyte ratio; PLR, platelet to lymphocyte ratio, LAP, Lymphadenopathy, PTCD, percutaneous transhepatic cholangiography drainage; ICCA, intrahepatic cholangiocarcinoma; ECCA, extrahepatic cholangiocarcinoma; GB: gallbladder; CEA, carcinoembryonic antigen.